Analysts Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Target Price at $17.83

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $17.83.

VYGR has been the subject of several recent research reports. StockNews.com lowered Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 13th. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Wednesday, July 31st. Wedbush decreased their price target on Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $18.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, May 15th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Great Point Partners LLC purchased a new stake in shares of Voyager Therapeutics in the second quarter worth about $12,668,000. Farallon Capital Management LLC boosted its position in Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company's stock worth $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock worth $30,087,000 after purchasing an additional 702,030 shares during the period. American Century Companies Inc. grew its stake in shares of Voyager Therapeutics by 32.4% during the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company's stock worth $8,063,000 after purchasing an additional 249,659 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Voyager Therapeutics during the 4th quarter valued at approximately $1,569,000. Hedge funds and other institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Trading Down 2.0 %

Voyager Therapeutics stock traded down $0.13 during midday trading on Wednesday, hitting $6.47. The stock had a trading volume of 324,760 shares, compared to its average volume of 679,376. Voyager Therapeutics has a 52-week low of $6.06 and a 52-week high of $11.72. The company has a market capitalization of $352.81 million, a PE ratio of -129.37 and a beta of 0.96. The firm's fifty day moving average is $8.21 and its two-hundred day moving average is $8.37.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.20. The company had revenue of $29.58 million during the quarter, compared to the consensus estimate of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter in the prior year, the firm posted ($0.51) EPS. As a group, equities research analysts predict that Voyager Therapeutics will post -1.47 earnings per share for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.